SPK-8011
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Spark Therapeutics’ SPK-8011 is an adeno-associated virus-mediated gene therapy, aiming to restore normal clotting function to patients with hemophilia A. SPK-8011 delivers B domain-deleted coagulation factor VIII (fVIII), and encodes the same amino acid sequence as found in the widely used recombinant product Xyntha (Pfizer). SPK-8011 is currently midway through a Phase II trial that the company is wholly funding, unlike its gene therapy candidate for hemophilia B, SPK-9001, which is partnered to Pfizer for development and commercialization.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 SPK-8011 : Hemophilia
LIST OF FIGURES
8 Figure 1: SPK-8011 for hemophilia – SWOT analysis
LIST OF TABLES
6 Table 1: SPK-8011 drug profile
7 Table 2: SPK-8011 Phase II data in hemophilia
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
SPK-9001 
Sign up to the